Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Acquisitions (2020 - 2021)

Anika Therapeutics (ANIK) has disclosed Acquisitions for 2 consecutive years, with $113000.0 as the latest value for Q4 2021.

  • On a quarterly basis, Acquisitions fell 84.77% to $113000.0 in Q4 2021 year-over-year; TTM through Sep 2022 was $113000.0, a 89.77% decrease, with the full-year FY2021 number at $476000.0, down 99.5% from a year prior.
  • Acquisitions was $113000.0 for Q4 2021 at Anika Therapeutics, up from $11000.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $93.0 million in Q1 2020 to a low of $2000.0 in Q2 2021.